GlassScriptPhysician profile
Christa R Henderson
NPI 1942270517
$5,567.61
in general payments reported to CMS, 2019-2025
30 companies · $1,512 in 2025
The $1,512 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $430 · 2022: $354 · 2023: $1,833 · 2024: $1,439 · 2025: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,005 · Travel and Lodging: $779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,005.37 |
| Travel and Lodging | $778.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,151.46 | 2022-2024 | Linq II, Aurora Ev-Icd Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $898.73 | 2022-2025 | Lifevest |
| Pfizer INC. | $398.72 | 2022-2025 | |
| Aop Health US, LLC | $368.95 | 2025 | Rapiblyk |
| Boston Scientific Corporation | $262.90 | 2021-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.98 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $231.59 | 2023-2025 | Camzyos, Eliquis |
| Abiomed | $217.28 | 2024-2025 | Impella |
| Cvrx, INC. | $197.80 | 2021-2023 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $169.56 | 2022-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $136.86 | 2022-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $130.77 | 2021-2024 | Xarelto |
| Esperion Therapeutics, INC. | $129.81 | 2022-2025 | Nexletol |
| Kestra Medical Technology Services, INC. | $126.44 | 2023-2025 | Assure Wcd |
| Abbott Laboratories | $124.17 | 2021-2024 | Gallant, Cardiomems |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $112.95 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $94.35 | 2022-2025 | Repatha, Repatha |
| Biotronik INC. | $88.65 | 2025 | Acticor 7 Vr-T Dx |
| Scpharmaceuticals INC. | $75.58 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.49 | 2022-2025 | |
| Irhythm Technologies, INC. | $64.05 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Novartis Pharmaceuticals Corporation | $55.32 | 2021-2024 | |
| Cardiovascular Systems INC. | $42.22 | 2021 | |
| Azurity Pharmaceuticals, INC. | $37.54 | 2023-2024 | Edarbi, Edarbi |
| Kiniksa Pharmaceuticals International, Plc | $34.79 | 2024 | Arcalyst |
| Biogen, INC. | $20.73 | 2024 | Skyclarys |
| Kiniksa Pharmaceuticals, LTD. | $19.31 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $18.86 | 2025 | Uptravi |
| Lexicon Pharmaceuticals, INC. | $18.05 | 2024 | |
| Edwards Lifesciences Corporation | $14.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christa Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.